Search
Massachusetts Paid Clinical Trials
A listing of 3221 clinical trials in Massachusetts actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
3013 - 3024 of 3221
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Location
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Massachusetts is currently home to 3221 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boston, Worcester, Springfield and Burlington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
Recruiting
This is an open-label, multi-center, phase 1b study designed to determine a tolerable dose of CX-5461 administered by IV infusion on Day 1 and Day 8 of a 28-day cycle in patients with selected solid tumours and associated mutations for future Phase II trials. The safety and tolerability of CX-5461, preliminary evidence of antitumor effect and the effect of CX-5461 on the Health-Related Quality of Life (HRQoL) will also be evaluated. The study will also evaluate the predictive value of mutational... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/02/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Advanced Solid Tumor
Comparison of the Q-NRG+ Indirect Calorimetry Device Versus the V(Max) Encore Device in Mechanically Ventilated Children
Recruiting
The overarching aim of this proposal is to examine the feasibility of the Q-NRG+ indirect calorimetry device and its agreement with (Vmax) Encore indirect calorimetry device in mechanically ventilated children. The overall hypothesis of this study is that the Q-NRG+ will provide minute-to-minute oxygen consumption (VO2) and carbon dioxide production (CO2) measurements that are in agreement with those obtained by the standard indirect calorimetry device currently used at our institution (Vmax Enc... Read More
Gender:
ALL
Ages:
Between 10 years and 18 years
Trial Updated:
12/31/2023
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Calorimetry, Indirect, Oxygen Consumption, Metabolism, Mechanical Ventilation
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Recruiting
CLN-049-001 is a Phase 1, open-label, multicenter, first-in-human trial of CLN-049 in patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/22/2023
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Conversational Agent Vaccine Promotion RCT
Recruiting
The objective of this study is to assess the use of and satisfaction with the ECA intervention over a 12-month period, its ability to increase SARS-CoV-2 and influenza vaccination in the BMATP community, and the comparative effectiveness of proactive engagement strategies and cultural tailoring on these factors. The Investigators will assess app use and satisfaction among these participants, along with self-reported vaccination attitudes and behavior, at 6 months and 12 months.
During this time... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/21/2023
Locations: Northeastern University, Boston, Massachusetts
Conditions: Pandemics
A Study to Evaluate DAY101 in Pediatric and Young Adult Patients With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
Recruiting
FIREFLY-1 is an ongoing, Phase 2, multi center, open-label study to evaluate the safety and efficacy of oral pan-RAF inhibitor DAY101 in pediatric, adolescent, and young adult patients with recurrent or progressive low-grade glioma or an advanced solid tumor harboring a known RAF alteration.
Gender:
ALL
Ages:
Between 6 months and 25 years
Trial Updated:
12/21/2023
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Low-grade Glioma, Advanced Solid Tumor
Building Resiliency in Dyads of Patients With an ANI Admitted to the Neuro-ICU and Their Informal Caregivers
Recruiting
The purpose of the present investigation is to test the efficacy of a brief (6 sessions) dyadic (patient and caregiver together) intervention to prevent chronic emotional distress in at risk dyads admitted to a Neuroscience Intensive Care Unit with an acute brain injury. Through this study, we seek to solve the unmet need of preventing chronic emotional distress in Neuroscience Intensive Care Unit (NICU) dyads through a feasible, acceptable and credible program, and ideally improve the recovery... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/20/2023
Locations: Massachusetts General Hospital (MGH), Boston, Massachusetts
Conditions: Acute Neurological Injury, Emotional Distress
A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma
Recruiting
The purpose of this observational research study is to follow participants who have been treated with either bel-sar or received alternate treatment (sham, standard of care therapy, etc.) while participating in a previous Aura Biosciences clinical research study to assess the long-term safety and effectiveness in these subjects. This study will collect information from procedures conducted as part of routine follow-up eye care and cancer care. Additionally, the registry will collect all adverse... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/20/2023
Locations: Massachusetts Eye and Ear Infirmary, Boston, Massachusetts
Conditions: Choroidal Melanoma, Indeterminate Lesions of Eye
Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors
Recruiting
To evaluate CAN1012(Selective TLR7 agonist) when administered by IT injection to subjects with advanced solid tumors who are not candidates for standard therapy.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
12/18/2023
Locations: CanWellPharma, Woburn, Massachusetts
Conditions: Solid Tumor, Cancer Metastatic
Investigate the Efficacy and Safety of Farudodstat Compared With Its Placebo in Adult Alopecia Areata Participants
Recruiting
The main purpose of this study is to measure the efficacy of farudodstat compared to placebo at Week 12 from the treatment start, in adult participants with Alopecia Areata (AA) with 30% or greater scalp hair loss.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2023
Locations: 1 Site, Brighton, Massachusetts
Conditions: Alopecia Areata
Salivary Extracellular Vesicle Associated lncRNAs in Heart Failure (SEAL-HF)
Recruiting
The purpose of this study is to determine the relationship between the levels of Ribonucleic acid (RNA) circulating molecules, including ones in extracellular vesicles from different organs in the blood and in the saliva of patients with Acute Decompensated Heart Failure (ADHF) and Chronic Heart Failure (CHF) to see if a new, non-invasive diagnostic test can be developed for heart failure exacerbation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/05/2023
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: CHF, ADHF, Control
International CDKL5 Clinical Research Network
Recruiting
Pathogenic variants in the Cyclin-dependent kinase like 5 (CDKL5) gene cause CDKL5 deficiency disorder (CDD, MIM 300672, 105830), a severe developmental and epileptic encephalopathy associated with cognitive and motor impairments and cortical visual impairment. While capability for disease modifying therapies is accelerating, there is a critical barrier for clinical trial readiness that may result in failure of these therapies, not due to lack of efficacy but due to lack of validated outcome mea... Read More
Gender:
ALL
Ages:
Between 1 month and 100 years
Trial Updated:
12/05/2023
Locations: Harvard Medical School/Boston Children's Hospital, Boston, Massachusetts
Conditions: CDKL5, CDKL5 Deficiency Disorder, CDD
PET Fibrin Imaging of DVT and PE
Recruiting
This study aims to investigate a novel positron emission tomography(PET)-probe for imaging of fresh intravascular blood clots in pulmonary embolism (PE) and deep venous thrombosis (DVT).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/05/2023
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Pulmonary Embolism, Deep Vein Thrombosis, Venous Thromboembolism